Latest News for ESALF
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for…
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ESALF.
Senate Trading
No Senate trades found for ESALF.
U.S. House Trading
No House trades found for ESALF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.